全文获取类型
收费全文 | 3279212篇 |
免费 | 267117篇 |
国内免费 | 14057篇 |
专业分类
耳鼻咽喉 | 44883篇 |
儿科学 | 102957篇 |
妇产科学 | 83858篇 |
基础医学 | 521607篇 |
口腔科学 | 86872篇 |
临床医学 | 289753篇 |
内科学 | 579941篇 |
皮肤病学 | 87255篇 |
神经病学 | 283224篇 |
特种医学 | 128909篇 |
外国民族医学 | 374篇 |
外科学 | 514191篇 |
综合类 | 98710篇 |
现状与发展 | 25篇 |
一般理论 | 2375篇 |
预防医学 | 275542篇 |
眼科学 | 73907篇 |
药学 | 223092篇 |
23篇 | |
中国医学 | 9489篇 |
肿瘤学 | 153399篇 |
出版年
2021年 | 55366篇 |
2020年 | 35325篇 |
2019年 | 58432篇 |
2018年 | 71433篇 |
2017年 | 54564篇 |
2016年 | 60192篇 |
2015年 | 74405篇 |
2014年 | 108727篇 |
2013年 | 174251篇 |
2012年 | 93726篇 |
2011年 | 94344篇 |
2010年 | 117441篇 |
2009年 | 121816篇 |
2008年 | 81786篇 |
2007年 | 85084篇 |
2006年 | 95366篇 |
2005年 | 91698篇 |
2004年 | 93241篇 |
2003年 | 84048篇 |
2002年 | 73779篇 |
2001年 | 89826篇 |
2000年 | 82310篇 |
1999年 | 85490篇 |
1998年 | 64045篇 |
1997年 | 62215篇 |
1996年 | 59888篇 |
1995年 | 55273篇 |
1994年 | 49479篇 |
1993年 | 46169篇 |
1992年 | 58811篇 |
1991年 | 55478篇 |
1990年 | 52665篇 |
1989年 | 51991篇 |
1988年 | 48563篇 |
1987年 | 47489篇 |
1986年 | 45498篇 |
1985年 | 45724篇 |
1984年 | 43309篇 |
1983年 | 40163篇 |
1982年 | 40064篇 |
1981年 | 37786篇 |
1980年 | 35764篇 |
1979年 | 35240篇 |
1978年 | 32310篇 |
1977年 | 29848篇 |
1976年 | 27408篇 |
1975年 | 25931篇 |
1974年 | 26410篇 |
1973年 | 25249篇 |
1972年 | 23751篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Henk R Franke F Froukje Snaaijer Paul W H Houben Marius J van der Mooren 《Gynecological endocrinology》2006,22(12):692-697
OBJECTIVE: To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women. METHODS: In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score). RESULTS: Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups. CONCLUSIONS: Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss. 相似文献
993.
I. DIMOVA B. ZAHARIEVA S. RAITCHEVA† R. DIMITROV‡ N. DOGANOV‡ & D. TONCHEVA 《International journal of gynecological cancer》2006,16(1):145-151
The objective of this study was to assess the implication of copy number changes of epidermal growth factor receptor (EGFR) and erbB2 genes in the etiology and progression of ovarian tumors. In our study, we used the highly reliable method of fluorescent in situ hybridization, applied on tissue microarray, containing 1006 ovarian tumors from different malignancy, histologic type and grade, and tumor stage, in order to analyze the correlations between gene copy number changes and tumor phenotype. We established copy number changes of erbB2 in 15.30% of malignant ovarian tumors-8.16% amplifications and 7.14% gains. The frequency of EGFR copy number changes was 10.67%-3.65% amplifications and 7.02% gains. EGFR gains occurred with approximately the same frequency in malignant (7.02%), low malignant potential (8.33%), and benign (7.19%) ovarian tumors. ErbB2 amplification was associated with clear cell type of ovarian cancer (P < 0.04). No amplification of EGFR and erbB2 genes was established in tumors with low malignant potency and in benign tumors. Regarding cancer phenotype, there was no statistically significant association between erbB2 copy number changes and histologic grade as well as tumor stage of ovarian cancer. EGFR gains are early events in ovarian tumorigenesis. Our results showed similar frequencies of EGFR gains in different grade tumors, while EGFR amplification increased from grades 1 to 2 to 3. 相似文献
994.
M. RAUVALA K. AGLUND† U. PUISTOLA T. TURPEENNIEMI-HUJANEN‡ G. HORVATH§ R. WILLÉN & U. STENDAHL† 《International journal of gynecological cancer》2006,16(3):1297-1302
The incidence of uterine cervical cancer has increased slightly in Western countries, with an increase in relatively young women. Overexpression of matrix metalloproteinases (MMPs)-2 and -9 has turned out as a prognostic factor in many cancers. We compared the expression of the proteins MMP-2 and MMP-9 in cervical primary tumors with clinical outcome and risk factors of cervical cancer. One hundred sixty-one patients with cervical cancer treated in Ume? University Hospital or Sahlgrenska University Hospital, Sweden, between 1991 and 1995 were included in the study. Paraffin-embedded tissue samples obtained prior to treatment were examined immunohistochemically by specific antibodies for MMP-2 and MMP-9. Forty-two percent of the tumors were intensively positive for MMP-2 and 31% for MMP-9. Nineteen percent of the samples were intensively positive for both proteinases and 47% negative or weak for both. Overexpression of MMP-2 seemed to predict unfavorable survival under Kaplan-Meier analysis and in the multivariate analysis. Early sexual activity and low parity seemed to correlate to overexpression of MMP-2. MMP-9 was not associated with survival or sexual behavior. Intensive MMP-9 was noted in grade 1 tumors. We conclude that MMP-2 and MMP-9 have different roles in uterine cervical cancer. MMP-2 could be associated with aggressive behavior, but MMP-9 expression diminishes in high-grade tumors. 相似文献
995.
C. TASKIRAN K. YUCE P.O. GEYIK† T. KUCUKALI‡ & A. AYHAN 《International journal of gynecological cancer》2006,16(3):1342-1347
The purpose of this study was to predict lymphatic involvement in endometrial cancer using clinicopathologic variables of patients treated with surgical staging. Overall, 461 patients treated with an initial surgical staging procedure including complete pelvic-para-aortic lymphadenectomy were included. The mean number of resected lymph nodes was 27 (median 26; range 15-83), and 54 patients (12%) had lymphatic involvement. Of these patients, 32 had only pelvic, 15 had both pelvic and para-aortic, and 7 had isolated para-aortic metastases. In the multivariate analysis, deep myometrial invasion (P= 0.02), lymphvascular space invasion (P= 0.001), positive peritoneal cytology (P= 0.002), and cervical involvement (P= 0.003) predicted retroperitoneal lymph node metastasis (RLN) significantly. Two hundred seventy-four patients (59.4%) had at least one of these poor prognostic factors identified by multivariate analysis. In this patient population, 53 (19.3%) had lymphatic involvement compared to 1 patient in the group of 187 patients with low-risk criteria. Ninety-eight percent of patients with RLN were predicted by this model, and with the advent of accurate diagnostic techniques, 40% of patients could be saved from undergoing lymphadenectomy. 相似文献
996.
997.
998.
In a retrospective study using univariate analysis, we identified tumor type (nonendometrioid vs endometrioid), depth of myoinvasion (MI), mode of MI (infiltrative vs cohesive), and direct anatomic invasion of the cervical wall from the isthmus as significant positive risk factors for intramyometrial lymphvascular space involvement (LVSI). On multivariate analysis, tumor grade, depth of MI, and mode of MI retained their significance. We created a grid for the relative risks of LVSI with respect to these variables individually or in combination. We suggest that our indirect estimate of the risk of LVSI can help in assessing prognosis and determining the need for adjuvant therapy whenever LVSI is important in clinical decision making, but its pathologic diagnosis is uncertain. 相似文献
999.
1000.
G. Kahlmeter D. F. J. Brown F. W. Goldstein A. P. MacGowan J. W. Mouton I. Odenholt A. Rodloff C-J. Soussy M. Steinbakk F. Soriano O. Stetsiouk 《Clinical microbiology and infection》2006,12(6):501-503
The main objectives of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are to harmonise breakpoints for antimicrobial agents in Europe, and to act as the breakpoint committee for the European Medicines Agency (EMEA) during the registration of new antimicrobial agents. Detailed EUCAST procedures for harmonising and setting breakpoints for antimicrobial agents are available on the EUCAST website. Beginning with the current issue, a series of EUCAST Technical Notes will be published in CMI, based on the rationale documents produced by EUCAST for each of the antimicrobial agents studied, with the aim of highlighting important background information underlying decisions on breakpoints made by EUCAST. 相似文献